Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

This study looked at 317 biomarker-evaluable patients with previously ... clinical efficacy in KRASG12C-mutated non-small-cell lung cancer, Nature Medicine (2025). DOI: 10.1038/s41591-025-03732-5 ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Cancer patients found to have specific gene mutations or other biomarkers are being matched to precision treatments not ...

More than one quarter of the medcines cleared by the FDA’s main review office since 2015 have been cancer drugs, a tally that ...

Quest plans to refine, develop and validate the technology and is aiming to launch the test in North America next year.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

Insilico Medicine, the biotech company with twin headquarters in Boston and Hong Kong, said it’s the first time an AI-created ...